174 related articles for article (PubMed ID: 31704870)
1. Radiotherapy Plus GnRH Analogue
Buwenge M; Deodato F; Macchia G; Siepe G; Zhao X; Valicenti RK; Cilla S; Alitto AR; Ntreta M; Bisello S; Mantini G; Valentini V; Morganti AG; Cammelli S
Anticancer Res; 2019 Nov; 39(11):6373-6378. PubMed ID: 31704870
[TBL] [Abstract][Full Text] [Related]
2. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
[TBL] [Abstract][Full Text] [Related]
4. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita H; Kawakami S; Fukui I
Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
[No Abstract] [Full Text] [Related]
5. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
[TBL] [Abstract][Full Text] [Related]
6. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
7. Intermittent versus continuous androgen deprivation in prostate cancer.
Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
[TBL] [Abstract][Full Text] [Related]
8. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.
Ueda T; Shiraishi T; Ito S; Ohashi M; Matsugasumi T; Yamada Y; Fujihara A; Hongo F; Okihara K; Ukimura O
Sci Rep; 2021 May; 11(1):10094. PubMed ID: 33980956
[TBL] [Abstract][Full Text] [Related]
10. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
11. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
12. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
13. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
[TBL] [Abstract][Full Text] [Related]
15. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
16. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
Akaza H; Hinotsu S; Usami M; Arai Y; Kanetake H; Naito S; Hirao Y;
Cancer; 2009 Aug; 115(15):3437-45. PubMed ID: 19536889
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Corn PG; Song DY; Heath E; Maier J; Meyn R; Kuban D; DePetrillo TA; Mathew P
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):540-5. PubMed ID: 23541810
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
Beebe-Dimmer JL; Ruterbusch JJ; Bylsma LC; Gillezeau C; Fryzek J; Schultz NM; Flanders SC; Barlev A; Heath E; Quek RGW
Adv Ther; 2018 Sep; 35(9):1438-1451. PubMed ID: 29946798
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]